Evidence map›Paper›PMID 22020828›Full record

ArticleHepatology international2012

Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score.

Hirotoshi Ebinuma, Hidetsugu Saito, Shinichiro Tada, Nobuhiro Nakamoto, Tazuko Ohishi, Satoshi Tsunematsu, Naoki Kumagai, Kanji Tsuchimoto, Nobuhiro Tsukada, Yasutaka Inagaki and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Hirotoshi EbinumaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Hidetsugu SaitoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. hsaito@sc.itc.keio.ac.jp.
Shinichiro TadaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Nobuhiro NakamotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Tazuko OhishiThe Center for Liver Diseases, Department of Internal Medicine, Kitasato Institute Hospital, Tokyo, Japan.
Satoshi TsunematsuThe Center for Liver Diseases, Department of Internal Medicine, Kitasato Institute Hospital, Tokyo, Japan.
Naoki KumagaiThe Center for Liver Diseases, Department of Internal Medicine, Kitasato Institute Hospital, Tokyo, Japan.
Kanji TsuchimotoThe Center for Liver Diseases, Department of Internal Medicine, Kitasato Institute Hospital, Tokyo, Japan.
Nobuhiro TsukadaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Saiseikai Central Hospital, Tokyo, Japan.
Yasutaka InagakiDepartment of Internal Medicine, Nihon Kohkan Hospital, Kawasaki, Japan.
Yoshinori HorieDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Eiju General Hospital, Tokyo, Japan.
Masahiko TakahashiDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Kazuhiro AtsukawaDepartment of Gastroenterology and Hepatology, Hiratsuka City Hospital, Hiratsuka, Japan.
Yukishige OkamuraDepartment of Internal Medicine, Sanokousei Hospital, Sano, Japan.
Takanori KanaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Toshifumi HibiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Keio University · JPKitasato Institute Hospital · JPEiju General Hospital · JPHiratsuka City Hospital · JPKawasaki Hospital · JPNational Hospital Organization · JPSaiseikai Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePeginterferon (PEG-IFN) and ribavirin (RBV) combination treatment for patients with chronic hepatitis C (CHC), infected by genotype-1 hepatitis C virus with high viral loads, results in a sustained viral response (SVR) in ~50%. However, a trend of decreasing SVR in the older patients has been reported. In the present study, we verified this trend of treatment efficacy in older patients using the propensity score (PS).

methodsWe conducted a survey of 327 patients with CHC (genotype 1 and high viral loads) who were treated with PEG-IFN and RBV for 48 weeks. The SVR rate was compared between patients =60 and <60 years of age. Because backgrounds of these patients differed considerably, we verified this efficacy between the older (n = 102) and younger (n = 102) patients matched for gender, body weight, platelets (PLT), and red blood cell (RBC) counts using PS.

resultsThe total SVR rate was 42.9% (161/327); this rate decreased with increasing age and was lower in the older patients (≥60 years: 41.5%, <60 years: 54.3%, P = 0.0245). Moreover, younger age was a significant factor for SVR. After correction by PS, the SVR in older patients remained significantly lower (≥60 years: 43.1%, <60 years: 57.8%, P = 0.0497). In addition, RBC counts and hemoglobin (Hgb) concentrations, as well as RBV adherence in the older patients, decreased with this treatment, although there were no significant differences in pretreatment RBC and Hgb levels.

conclusionsThe analysis using PS indicated that RBV adherence in the older patients decreased even if they did not have lower pretreatment RBC and Hgb levels.

Indexed as

Chronic hepatitis CPropensity scoreRibavirin adherenceThe combination treatment of peginterferon and ribavirinThe elderly patients

Identifiers

PMID22020828
OpenAlexW2073711959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.